NASDAQ
05.08.25 | 21:59
5,350 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 39 | GlobeNewswire (Europe) | SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 02.07. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 63 | GlobeNewswire (Europe) | SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 13.06. | Olema Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.06. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 111 | GlobeNewswire (Europe) | SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 29.05. | H.C. Wainwright maintains Buy on Olema Pharma, $28 target | 3 | Investing.com | ||
| OLEMA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 28.05. | Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 14.05. | Olema Pharmaceuticals stock target cut to $28 by H.C. Wainwright | 2 | Investing.com | ||
| 13.05. | Olema Oncology Reports First Quarter 2025 Financial and Operating Results | 132 | GlobeNewswire (Europe) | Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from... ► Artikel lesen | |
| 02.05. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 182 | GlobeNewswire (Europe) | SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 25.04. | Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 | 2 | GlobeNewswire (USA) | ||
| 02.04. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 138 | GlobeNewswire (Europe) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 25.03. | Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 19.03. | HC Wainwright maintains $30 target on Olema Pharma stock | 1 | Investing.com | ||
| 18.03. | Olema Pharmaceuticals GAAP EPS of -$0.51 | 2 | Seeking Alpha | ||
| 18.03. | Olema Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Olema Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 18.03. | Olema Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results | 493 | GlobeNewswire (Europe) | Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in combination... ► Artikel lesen | |
| 06.03. | Olema Pharmaceuticals stock holds $30 target at H.C. Wainwright | 4 | Investing.com | ||
| 05.03. | Olema Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,50 | -0,52 % | Trumps Zölle & Übernahmen! BioNTech, PanGenomic Health, Pfizer und Valneva im Visier der Spekulanten | Nun ist die USA-EU-Zollbeziehung beschlossen. Für viele Sektoren der Wirtschaft kommt es in Europa nun zu Sonderbelastungen und Margeneinschnitten. Verschont bleibt die BioTech- und Pharmabranche, denn... ► Artikel lesen | |
| CUREVAC | 4,668 | -0,93 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| AMGEN | 257,55 | -0,77 % | Prognose-Schock vs. Prognose-Boost - Zalando, Fresenius, Beiersdorf, Qiagen, Super Micro, AMD, Amgen | Der DAX hat sich gestern erneut gut geschlagen und an die starke Performance vom Montag angeknüpft. Es gab zwar die eine oder andere Schwächephase. Trotzdem schloss der DAX 0,37 Prozent höher bei 23.846... ► Artikel lesen | |
| NOVAVAX | 6,179 | +6,00 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
| BIOGEN | 113,95 | -0,83 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
| MAINZ BIOMED | 1,510 | 0,00 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,365 | -0,10 % | Is Viking Therapeutics the Next Big Biotech Bet? | ||
| INTELLIA THERAPEUTICS | 10,005 | +0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| GENMAB | 187,90 | -1,85 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Second Quarter of 2025 | Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,316 | +1,19 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| TEMPUS AI | 49,400 | -1,20 % | If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today | ||
| SAREPTA THERAPEUTICS | 14,180 | -1,97 % | Sarepta-Aktie: +87,8% über Nacht - Sharedeals-Leser feiern | Bei Sarepta Therapeutics explodiert der Kurs innerhalb von wenigen Stunden nach einem exklusiven Tipp auf sharedeals.de. Was steckt hinter dem Coup - und wie findest Du den nächsten Depot-Turbo? Gideon... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,034 | -11,17 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx in Acute Myocarditis | Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx over placebo.Reduction in ECV was associated with improvements... ► Artikel lesen | |
| EXELIXIS | 32,020 | -1,05 % | Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors | - Approval is based on the phase 3 CABINET pivotal trial, in which CABOMETYX demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,212 | -0,92 % | Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models |
Das Unternehmen OLEMA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OLEMA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.